DYMELOR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYMELOR is an oral small-molecule tablet approved by Eli Lilly in 1964 for diabetes management. The specific indication and mechanism of action are not detailed in available data, but it represents a legacy antidiabetic product from the early oral agent era. As a 60-year-old NDA, it is a foundational therapy in the company's endocrinology portfolio.
LOE Approaching
Legacy product with moderate competitive pressure (30/100) facing lifecycle decline; expect shrinking brand teams and focus shift toward generics support and international markets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DYMELOR offers limited career momentum; roles are maintenance-focused rather than growth-oriented, suitable for professionals seeking stable compliance or operational experience rather than launching innovation. Career trajectories here typically lead laterally to higher-potential products or out of pharmaceutical commercial roles entirely.
Brand Manager (legacy/management)
Worked on DYMELOR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.